3D DOSE ESCALATION FOR PROSTATE CANCER

前列腺癌的 3D 剂量递增

• 批准号: 2100975
• 负责人: Theodore Phillips
• 金额: $ 7.48万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-06-01 至 1997-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2100975
• 关键词: cancer information system; clinical trials; computer data analysis; cooperative study; cytotoxicity; data collection; human morbidity; human subject; human therapy evaluation; male; neoplasm /cancer radiation therapy; prostate neoplasms; radiation therapy dosage; seminal vesicles

This application is in response to a request for application for studies of the use of 3-D conformal radiotherapy (3DCRT) in the definitive treatment of prostate cancer. UCSF is prepared to work with the NCI, the operations and quality assurance center and other successful applicants in designing and conducting clinical trials of 3DCRT. It is expected that initial studies will be phase I/II dose searching protocols and that after these are completed a phase III trial will be designed and carried out. The local control rate in advanced prostate cancer is relatively low and (based on recent PSA and biopsy data) patients with more limited stages have a lower local control than previously thought. It is possible that the higher doses that are possible with 3DCRT without an increase in morbidity could lead to improved cure rates. UCSF has all of the required computer hardware and an excellent 3-D treatment planning system which meets all of the requirements of the RFA. It is expected that in 1992 the UCSF group will treat 144 prostate patients with curative intent. Since 1989 the group has treated 215 prostate patients with conformal plans, 109 with a 2.5-D system and 106 with the full 3-D system. Extensive analyses have been carried out of our experience which have yielded information on the risk of nodal metastases , selection of patients for trials evaluating local control, definition of margins to be treated around the prostate and evaluation of set-up variation. We analyzed various conformal and non-conformal plans with dose volume histograms and identified a 6 field conformal technique using partial transmission blocks which compared to more conventional non-conformal techniques, allows a potential increase in dose on the order of 20%. The experience of the group in treating this number of patients with CT conformal plans, our experience in the RTOG 3DCRT committee and the studies mentioned above will assist the UCSF group in working closely under the RFA group to design optimal protocols.

此申请是响应申请研究的请求 在确定性中使用3-D共形放疗（3DCRT） 治疗前列腺癌。 UCSF准备与NCI合作， 运营和质量保证中心以及其他成功的申请人 在设计和进行3DCRT的临床试验中。 预计 最初的研究将是I/II期剂量搜索方案，并且 完成后，将设计和携带III期试验 出去。 晚期前列腺癌的局部控制率相对 低和（基于最近的PSA和活检数据）患者 阶段的本地控制要比以前想象的要低。 这是 3DCRT可能没有的较高剂量 发病率的增加可能导致治愈率提高。 UCSF拥有所有 所需的计算机硬件和出色的3D处理计划 满足RFA的所有要求的系统。 预计 在1992年，UCSF组将治疗144名前列腺患者 治愈意图。 自1989年以来，该小组已经治疗了215名前列腺患者 具有共形计划，109带有2.5-D系统和106个带有完整的3-D 系统。 我们的经验已经进行了广泛的分析 已经产生了有关淋巴结转移风险的信息，选择 评估当地控制的试验患者，边缘的定义为 围绕前列腺治疗和设置变化的评估。 我们 分析了各种剂量量的各种保形计划和非统一计划 直方图并使用部分鉴定了6个场合形技术 传输块与更常规的非统一形式相比 技术，允许以20％的订单剂量增加。 这 该组治疗这一数量的CT患者的经验 共形计划，我们在RTOG 3DCRT委员会中的经验和 上面提到的研究将帮助UCSF集团密切合作 在RFA组下设计最佳协议。